(PharmaNewsWire.Com, February 28, 2018 ) The Europe Cancer Vaccines Market was worth $ 0.74 billion in 2016 and estimated to reach $ 1.58 billion by the end of 2021 with a growing potential of 16.29%
Therapeutic vaccines which are intended to treat an existing cancer by boosting the bodys natural immune response against cancer cells. Mostly, therapeutic vaccines are a form of immunotherapy. The numerous immune effector mechanisms mobilized by therapeutic vaccination precisely attack and destroy cancer cells and leave normal cells. Thus, therapeutic cancer vaccines, in general, may be used to inhibit further growth of advanced cancers, relapsed tumors that are refractory to conventional therapies, such as radiation therapy, surgery, and chemotherapy.
Europe cancer vaccines market is primarily driven by rising number of people with cancer, increasing public awareness of vaccines, smoking and excessive alcoholic intake, presence of strong late-stage pipeline Vaccines, vendors' patient-assistance programs are the major factors driving the growth of the market. stringent regulations for the approval, Vaccines costs are the factors limiting the growth of the market.
Based on Cancer type, the market is segmented into Prostate, Cervical, Colorectal, Throat, and others. Based on Vaccine type, the market is segmented into Protein and Peptide based , Tumour cell, Dendritic cell, Genetic vaccines and Others. Based on End Users, the market is segmented into Cancer Treatment Centres and Research Institutes. Based on Geography, Europe Cancer Vaccines Therapeutics market is analysed under various regions namely U.K, Germany, France, Italy and Spain.
Key players of Europe cancer vaccines market are Dendreon, GlaxoSmithKline and Merck. Companies with their products in pipeline are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech
Market Segmentation Treatment type Prophylactic Therapeutic Y-o-Y Growth Analysis, By Cancer Type Market Attractiveness Analysis, By Cancer type Market Share Analysis, By Cancer Type
Cancer Type Introduction Prostate Cancer Cervical Cancer Colorectal Cancer Throat Cancer Others
Vaccine Type Introduction Tumour cell Vaccines Protein or Peptide Vaccines Genetic Vaccines
End Users Introduction Cancer Treatment Centers Research Institutes Y-o-Y Growth Analysis, By End User Market Attractiveness Analysis, By End User Market Share Analysis, By End User
About Market Data Forecast: The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the clients research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Global among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: